


Bleomycin

| | |
|-----------|---|
| Cat. No.: | HY-108345 |
| CAS No.: | 11056-06-7 |
| Target: | Antibiotic |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | | |
|-------------------------------------|--|--|---------------|--|---------|----------------|-----------------|---|---------|--|
| Description | Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy ^{[1][2][3][4]} . | | | | | | | | | |
| IC₅₀ & Target | Glycopeptide | | | | | | | | | |
| In Vitro | <p>Bleomycin (0-4 mU/mL; 1 h) induces double-strand break in V79 cells^[2].</p> <p>Bleomycin (0-1 mU/mL; 1 h) reduces migration of DNA from S-phase cells^[2].</p> <p>Bleomycin (0-3 µg/mL; 1 h) induces chromatid aberrations in G2 cells^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> | | | | | | | | | |
| In Vivo | <p>Bleomycin (1 mg and 10 µg; retro-orbitary sinus injection once) affects cells in mitosis, induces apoptosis in tumor models^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57Bl/6 mice with LPB and B16F0 tumours^[4]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg and 10 µg</td> </tr> <tr> <td>Administration:</td> <td>Retro-orbitary sinus injection; 1 mg and 10 µg once</td> </tr> <tr> <td>Result:</td> <td>Decreased in the fraction of cells in mitosis in both tumours, induced cell apoptosis after the electric pulses delivery, increased the amount of atypical cells in LPB tumours.</td> </tr> </table> | | Animal Model: | C57Bl/6 mice with LPB and B16F0 tumours ^[4] | Dosage: | 1 mg and 10 µg | Administration: | Retro-orbitary sinus injection; 1 mg and 10 µg once | Result: | Decreased in the fraction of cells in mitosis in both tumours, induced cell apoptosis after the electric pulses delivery, increased the amount of atypical cells in LPB tumours. |
| Animal Model: | C57Bl/6 mice with LPB and B16F0 tumours ^[4] | | | | | | | | | |
| Dosage: | 1 mg and 10 µg | | | | | | | | | |
| Administration: | Retro-orbitary sinus injection; 1 mg and 10 µg once | | | | | | | | | |
| Result: | Decreased in the fraction of cells in mitosis in both tumours, induced cell apoptosis after the electric pulses delivery, increased the amount of atypical cells in LPB tumours. | | | | | | | | | |

CUSTOMER VALIDATION

- MedComm. 2023 Jul 12;4(4):e319.
- Cancer Lett. 2023 Feb 15;558:216092.
- ACS Appl Mater Interfaces. 2019 Jan 16;11(2):1942-1950.
- Cell Death Dis. 2020 Nov 12;11(11):976.

-
- Cell Death Dis. 2020 Jun 15;11(6):464.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Olive PL, et al. Detection of DNA double-strand breaks through the cell cycle after exposure to X-rays, bleomycin, etoposide and 125I dUrd. Int J Radiat Biol. 1993 Oct;64(4):349-58.
- [2]. Allio T, Preston RJ. Increased sensitivity to chromatid aberration induction by bleomycin and neocarzinostatin results from alterations in a DNA damage response pathway. Mutat Res. 2000 Sep 20;453(1):5-15.
- [3]. Meki H, et al. In vivo evolution of tumour cells after the generation of double-strand DNA breaks. Br J Cancer. 2003 Jun 2;88(11):1763-71.
- [4]. Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer. 2005;5(2):102-112.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA